Starts & Stops: Abbott's Inherited Products Add To Spike In Suspensions

Starts & Stops is a regular feature highlighting Medtech Insight editors' picks of noteworthy medtech clinical trial initiations, completions and suspensions each month. This edition highlights an apparent trial-suspension spike in the past month, including three studies that were stopped by Abbott evaluating products it inherited from its acquisition of St Jude Medical.

Clinical Trial
Medtech Insight's Starts & Stops • Source: Shutterstock

There are many reasons why a clinical trial may be suspended. Typical explanations are insufficient patient enrollment or insufficient funding, but, sometimes, more serious events crop up that oblige the sponsor to halt a study.

In the past month, there was a significant spike in the number of medical device trial suspensions. Between early Jan. 9 and Feb. 8, 12 suspensions were recorded for Starts & Stops, compared to the previous month period when there were, at most, four suspensions. Among the companies suspending trials during the most recent period was Merit Medical Systems Inc

One of the trials, STAR, was an EU study, while the other, STAART, was a US study. Both were designed to evaluate Merit's ablation system for treating painful metastatic lesions in vertebral bodies and pairing this treatment with vertebral augmentation

More from Clinical Trials

More from R&D